Norvir (Ritonavir)

Ritonavir, the active ingredient in Norvir, is a protease inhibitor presented as an oral dosage form for oral use. It treats HIV‑1 infection and is also used as a pharmacokinetic booster to increase plasma levels of co‑administered protease inhibitors in patients requiring antiretroviral therapy.

GNH USA supplies Norvir as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Norvir is a protease inhibitor used within antiretroviral therapy to target HIV‑1 replication and to enhance the effectiveness of other protease inhibitors.

HIV‑1 infection: reduces viral load when combined with other antiretroviral agents. Pharmacokinetic booster: increases plasma concentrations of co‑administered protease inhibitors, allowing lower dosing. Combination antiretroviral regimens: contributes to sustained viral suppression as part of multi‑drug therapy.

Ritonavir may cause a range of adverse reactions, from mild to severe. Monitoring and reporting of side effects are essential during therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Diarrhea: loose stools occurring during treatment. - Headache: transient cranial pain. - Fatigue: reduced energy levels.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - QT prolongation: cardiac rhythm disturbance that may lead to arrhythmia. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Lipodystrophy: abnormal fat redistribution. - Hyperglycemia: increased blood glucose levels.

Before initiating ritonavir, clinicians should assess patient history and monitor for specific risks.

Liver function monitoring: check baseline enzymes and repeat periodically. Drug interaction review: evaluate concomitant medications for CYP3A4 substrates. Cardiac assessment: consider ECG in patients with known QT prolongation. Adherence counseling: emphasize importance of consistent dosing. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Ritonavir interacts with many drugs through CYP3A4 inhibition; careful management is required.

Major Interactions (Avoid): - Simvastatin: risk of severe myopathy and rhabdomyolysis. - Ergot derivatives (e.g., ergotamine): may cause ergotism. - Midazolam: can lead to profound sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Other protease inhibitors: dose adjustments may be needed. - Anticoagulants (e.g., warfarin): monitor INR for bleeding risk. - Oral contraceptives: efficacy may be reduced, consider alternative contraception.